Hypertension Diagnostics Stock Current Ratio
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Hypertension Diagnostics' long-term financial health and intrinsic value.
Hypertension |
Hypertension Diagnostics Company Current Ratio Analysis
Hypertension Diagnostics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Hypertension Diagnostics Current Ratio | 0.52 X |
Most of Hypertension Diagnostics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hypertension Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, Hypertension Diagnostics has a Current Ratio of 0.52 times. This is 87.16% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current ratio for all United States stocks is 75.93% higher than that of the company.
Hypertension Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hypertension Diagnostics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hypertension Diagnostics could also be used in its relative valuation, which is a method of valuing Hypertension Diagnostics by comparing valuation metrics of similar companies.Hypertension Diagnostics is currently under evaluation in current ratio category among its peers.
Hypertension Fundamentals
Return On Asset | 3.0E-4 | ||||
Profit Margin | (0.03) % | ||||
Operating Margin | 0.0002 % | ||||
Current Valuation | 5.26 M | ||||
Shares Outstanding | 52.39 M | ||||
Price To Earning | (0.03) X | ||||
Price To Sales | 0.15 X | ||||
Revenue | 3.79 M | ||||
Gross Profit | 954.47 K | ||||
EBITDA | 72.29 K | ||||
Net Income | (125.39 K) | ||||
Cash And Equivalents | 5.66 K | ||||
Total Debt | 4.69 M | ||||
Current Ratio | 0.52 X | ||||
Book Value Per Share | (0.09) X | ||||
Cash Flow From Operations | (389.28 K) | ||||
Earnings Per Share | (0) X | ||||
Beta | -0.92 | ||||
Market Capitalization | 730.42 K | ||||
Total Asset | 1.28 M | ||||
Retained Earnings | (30.68 M) | ||||
Working Capital | (857 K) | ||||
Current Asset | 277 K | ||||
Current Liabilities | 1.13 M | ||||
Z Score | -31.6 | ||||
Net Asset | 1.28 M |
Currently Active Assets on Macroaxis
USOI | Credit Suisse X Links | |
ULTY | Tidal Trust II | |
CONY | YieldMax N Option | |
BCAT | BlackRock Capital Allocation | |
PDI | Pimco Dynamic Income |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Hypertension Pink Sheet
If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |